BACKGROUND: The resting partial pressure of end-tidal carbon dioxide (Petco2) has been shown to reflect cardiac performance in acute care settings in patients with heart failure (HF). The purpose of the present study was to compare the prognostic ability of the partial pressure of Petco2 at rest to other commonly collected resting variables in patients with systolic HF. METHODS: A total of 353 patients (mean age 58.6+/-13.7, 72% male) with systolic HF were included in this study. All patients underwent cardiopulmonary exercise testing where New York Heart Association (NYHA) class, resting Petco2, peak oxygen consumption, and the minute ventilation/carbon dioxide production slope were determined. Subjects were then followed for major cardiac events (mortality, left ventricular assist device implantation implantation, urgent heart transplantation). RESULTS: There were 104 major cardiac events during the 23.6+/-17.0-month tracking period. Multivariate Cox regression analysis revealed NYHA class (chi2 28.7, P<.001), left ventricular ejection fraction (residual chi2 21.7, P<.001), and resting Petco2 (residual chi2 14.1, P<.001) were all prognostically significant and retained in the regression. In a separate Cox regression analysis, left ventricular ejection fraction (residual chi2 8.8, P=.003), NYHA class (residual chi2 7.7, P=.005), and resting Petco2 (residual chi2 5.7, P=.02) added prognostic value to the minute ventilation/carbon dioxide production slope (chi2 26.0, P<.001). CONCLUSION: Resting Petco2 can be noninvasively collected from subjects in a short period, at a low cost, and with no risk or discomfort to the patient. Given the prognostic value demonstrated in the present study, the clinical assessment of resting Petco2 in the HF population may be warranted.
BACKGROUND: The resting partial pressure of end-tidal carbon dioxide (Petco2) has been shown to reflect cardiac performance in acute care settings in patients with heart failure (HF). The purpose of the present study was to compare the prognostic ability of the partial pressure of Petco2 at rest to other commonly collected resting variables in patients with systolic HF. METHODS: A total of 353 patients (mean age 58.6+/-13.7, 72% male) with systolic HF were included in this study. All patients underwent cardiopulmonary exercise testing where New York Heart Association (NYHA) class, resting Petco2, peak oxygen consumption, and the minute ventilation/carbon dioxide production slope were determined. Subjects were then followed for major cardiac events (mortality, left ventricular assist device implantation implantation, urgent heart transplantation). RESULTS: There were 104 major cardiac events during the 23.6+/-17.0-month tracking period. Multivariate Cox regression analysis revealed NYHA class (chi2 28.7, P<.001), left ventricular ejection fraction (residual chi2 21.7, P<.001), and resting Petco2 (residual chi2 14.1, P<.001) were all prognostically significant and retained in the regression. In a separate Cox regression analysis, left ventricular ejection fraction (residual chi2 8.8, P=.003), NYHA class (residual chi2 7.7, P=.005), and resting Petco2 (residual chi2 5.7, P=.02) added prognostic value to the minute ventilation/carbon dioxide production slope (chi2 26.0, P<.001). CONCLUSION: Resting Petco2 can be noninvasively collected from subjects in a short period, at a low cost, and with no risk or discomfort to the patient. Given the prognostic value demonstrated in the present study, the clinical assessment of resting Petco2 in the HF population may be warranted.
Authors: G Michael Felker; Kirkwood F Adams; Marvin A Konstam; Christopher M O'Connor; Mihai Gheorghiade Journal: Am Heart J Date: 2003-02 Impact factor: 4.749
Authors: Constantinos H Davos; Wolfram Doehner; Mathias Rauchhaus; Mariantonietta Cicoira; Darrel P Francis; Andrew J S Coats; Andrew L Clark; Stefan D Anker Journal: J Card Fail Date: 2003-02 Impact factor: 5.712
Authors: Franz Hartmann; Milton Packer; Andrew J S Coats; Michael B Fowler; Henry Krum; Paul Mohacsi; Jean L Rouleau; Michal Tendera; Alain Castaigne; Stefan D Anker; Ildiko Amann-Zalan; Silke Hoersch; Hugo A Katus Journal: Circulation Date: 2004-09-20 Impact factor: 29.690
Authors: Stefan Krüger; Jürgen Graf; Dagmar Kunz; Tina Stickel; Peter Hanrath; Uwe Janssens Journal: J Am Coll Cardiol Date: 2002-08-21 Impact factor: 24.094
Authors: Ewa A Jankowska; Jolanta Pietruk-Kowalczyk; Robert Zymliński; Tomasz Witkowski; Beata Ponikowska; Tadeusz Sebzda; Krzysztof Rzeczuch; Ludmiła Borodulin-Nadzieja; Halina Hańczycowa; Waldemar Banasiak; Piotr Ponikowski Journal: Kardiol Pol Date: 2003-08 Impact factor: 3.108
Authors: Ross Arena; Marco Guazzi; Jonathan Myers; Paul Chase; Daniel Bensimhon; Lawrence P Cahalin; Mary Ann Peberdy; Euan Ashley; Erin West; Daniel E Forman Journal: Congest Heart Fail Date: 2012-04-26
Authors: Ross Arena; Jonathan Myers; Joshua Abella; Sherry Pinkstaff; Peter Brubaker; Brian Moore; Dalane Kitzman; Mary Ann Peberdy; Daniel Bensimhon; Paul Chase; Daniel Forman; Erin West; Marco Guazzi Journal: Circ Heart Fail Date: 2009-02-10 Impact factor: 8.790
Authors: Marco Guazzi; Volker Adams; Viviane Conraads; Martin Halle; Alessandro Mezzani; Luc Vanhees; Ross Arena; Gerald F Fletcher; Daniel E Forman; Dalane W Kitzman; Carl J Lavie; Jonathan Myers Journal: Circulation Date: 2012-09-05 Impact factor: 29.690
Authors: Daniel E Forman; Jonathan Myers; Carl J Lavie; Marco Guazzi; Bartolome Celli; Ross Arena Journal: Postgrad Med Date: 2010-11 Impact factor: 4.379
Authors: Thomas P Olson; Dustin L Denzer; William L Sinnett; Ted Wilson; Bruce D Johnson Journal: Clin Med Insights Circ Respir Pulm Med Date: 2013-09-05